Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2014. The report details a specific share repurchase transaction executed on May 27, 2014, authorized by shareholders at the Annual General Meeting held on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 160,752 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,646.00 pence; lowest price paid was 1,629.50 pence.
- Treasury Holdings (Settled): 493,444,212 shares (9.22% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,090,214 shares (10.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,857,132,658 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 160,752 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.17% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (493,444,212 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.17% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Note that the 4,857,132,658 shares in issue (excluding Treasury) serve as the denominator for shareholder notification requirements under FCA rules.